Amgen Inc (NASDAQ: AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics derived from cellular and molecular biology. Revenue comes from product sales of prescription medicines across oncology, inflammation, cardiovascular, bone health, and other therapeutic areas, sold primarily to wholesalers, specialty distributors, and healthcare providers. The 10-K filed 2026-02-13 references marketed products including biologics and small molecules, with BiTE bispecific T-cell engager technology noted as a platform. Amgen operates across the United States and internationally, with geographic area financial information disclosed in the filing. The company holds Biologics License Applications with the FDA and engages with the European Medicines Agency for EU approvals, reflecting a regulatory-dependent commercialization model. IP protection across its biologic portfolio and the high clinical and regulatory barriers to entry in biologics manufacturing represent structural advantages over generic competition, though biosimilar competition under the BPCIA is an explicit risk factor in the filing.

Revenue model

Transactional product sales of prescription biologic and small-molecule medicines to wholesalers, specialty distributors, and healthcare providers; reimbursement through Medicare, Medicaid, and private insurers drives effective net pricing.

Products and services

Marketed human therapeutics spanning oncology, inflammation, cardiovascular, and bone health; BiTE bispecific T-cell engager platform; biologics and biosimilars; pipeline product candidates in clinical development.

Customers and end markets

Wholesalers, specialty distributors, hospitals, and healthcare providers; end patients covered under Medicare, Medicaid (including 340B Drug Pricing Program), and commercial insurance; oncology, inflammation, cardiovascular, and bone health end markets.

Value-chain role

Fully integrated biopharmaceutical company: internal R&D, biologics manufacturing and distribution, and direct commercial operations; licensing and collaboration relationships with partners including AstraZeneca.

Geographic exposure

United States and international markets; geographic area financial information disclosed in FY2025 10-K filing; EU regulatory engagement through EMA and European Commission.

Source: SEC 10-K, filed 2026-02-13

Industry: Biological Products, (No Diagnostic Substances) Peers: AbbVie Inc Gilead Sciences, Inc Moderna Inc Regeneron Pharmaceuticals Inc Vertex Pharmaceuticals Inc